{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:57:40Z","timestamp":1784743060369,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejca.2021.12.037","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T08:09:02Z","timestamp":1645949342000},"page":"152-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-0512","authenticated-orcid":false,"given":"William","family":"Wesson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7977-4073","authenticated-orcid":false,"given":"Vincent L.","family":"Galate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McClune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishal","family":"Gyawali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saqib","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.12.037_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-020-0323-4","article-title":"Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century","volume":"10","author":"Pulte","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ejca.2021.12.037_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-021-00198-2","article-title":"A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990\u20132017","volume":"10","author":"Keykhaei","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ejca.2021.12.037_bib3","series-title":"Annual report to the nation on the status of cancer, Part 1: national cancer statistics","first-page":"djab131","author":"Islami","year":"2021"},{"key":"10.1016\/j.ejca.2021.12.037_bib4","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1080\/10428194.2021.1876872","article-title":"Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies","volume":"62","author":"Al Hadidi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2021.12.037_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jcpo.2018.07.003","article-title":"Why is research in early-stage cancer research so low?","volume":"17","author":"Prasad","year":"2018","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.ejca.2021.12.037_bib6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ajh.26166","article-title":"Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: a systematic review","volume":"96","author":"Mohyuddin","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2021.12.037_bib7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejca.2021.12.037_bib8","article-title":"Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology","volume":"287","author":"Sherrill","year":"2012","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ejca.2021.12.037_bib9","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaoncol.2016.4166","article-title":"Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines","volume":"3","author":"Salas-Vega","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.12.037_bib10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrclinonc.2017.72","article-title":"Combining drugs and extending treatment \u2014 a PFS end point is not sufficient","volume":"14","author":"Gyawali","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.037_bib11","series-title":"Clinical trial endpoints","author":"Sullivan","year":"2012"},{"key":"10.1016\/j.ejca.2021.12.037_bib12","series-title":"World economic situation and Prospects 2014","year":"2014"},{"key":"10.1016\/j.ejca.2021.12.037_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3810\/pgm.2011.09.2475","article-title":"Key concepts of clinical trials: a narrative review","volume":"123","author":"Umscheid","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.ejca.2021.12.037_bib14","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.1997.15.2.853","article-title":"Critical role of phase I clinical trials in cancer treatment","volume":"15","author":"Lawrence","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.037_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2020.04.037","article-title":"Phase I trials and therapeutic intent in the age of precision oncology: what is a patient's chance of response?","volume":"139","author":"Tao","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.12.037_bib16","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1001\/jama.292.17.2130","article-title":"Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials","volume":"292","author":"Roberts","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2021.12.037_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials","volume":"125","author":"Hariton","year":"2018","journal-title":"BJOG An Int J Obstet Gynaecol"},{"key":"10.1016\/j.ejca.2021.12.037_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13580","article-title":"Reliable, cheap, fast and few: what is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?","volume":"51","author":"Prasad","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejca.2021.12.037_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2106\/JBJS.L.00193","article-title":"Overcoming the funding challenge: the cost of randomized controlled trials in the next decade","volume":"94","author":"Shore","year":"2012","journal-title":"J Bone Jt Surg"},{"key":"10.1016\/j.ejca.2021.12.037_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ije\/dyp174","article-title":"How to assess the external validity of therapeutic trials: a conceptual approach","volume":"39","author":"Dekkers","year":"2010","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ejca.2021.12.037_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/pds.2067","article-title":"Assessing general side effects in clinical trials: reference data from the general population: GASE IN clinical trials","volume":"20","author":"Rief","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejca.2021.12.037_bib22","series-title":"Accelerated approval program","year":"2020"},{"key":"10.1016\/j.ejca.2021.12.037_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2021.12.037_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamainternmed.2013.3037","article-title":"Surrogate outcomes in clinical trials: a cautionary tale","volume":"173","author":"Svensson","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejca.2021.12.037_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaoncol.2020.7478","article-title":"An analysis of contemporary oncology randomized clinical trials from low\/middle-income vs high-income countries","volume":"7","author":"Wells","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.12.037_bib26","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the randomized clinical trial in the era of precision oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.12.037_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.critrevonc.2008.07.015","article-title":"Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia","volume":"69","author":"Alibhai","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2021.12.037_bib28","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","author":"Davis","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2021.12.037_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejca.2021.12.037_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41375-018-0363-y","article-title":"New study-designs to address the clinical complexity of acute myeloid leukemia","volume":"33","author":"Estey","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2021.12.037_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1634\/theoncologist.2012-0423","article-title":"Publicly funded clinical trials and the future of cancer care","volume":"18","author":"Schilsky","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2021.12.037_bib32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JOP.0834601","article-title":"Collaboration between cooperative groups and industry","volume":"4","author":"Bressler","year":"2008","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ejca.2021.12.037_bib33","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s11136-021-02826-0","article-title":"How is quality of life defined and assessed in published research?","volume":"30","author":"Costa","year":"2021","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2021.12.037_bib34","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1016\/S2352-3026(20)30292-1","article-title":"Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review","volume":"7","author":"Chakraborty","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2021.12.037_bib35","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2018.77.9124","article-title":"Progression-free survival as a surrogate end point for overall survival in first-line Diffuse Large B-Cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL)","volume":"36","author":"Shi","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2021.12.037_bib36","doi-asserted-by":"crossref","first-page":"100332","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922000478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922000478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:37:07Z","timestamp":1760733427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922000478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":36,"alternative-id":["S0959804922000478"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.037","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}